Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698035 · ClinicalTrials.gov registry record · Phase 2
Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients
A Phase 2 study of Sexual Dysfunction, Physiological, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT00698035 is a Phase 2 study of Sexual Dysfunction, Physiological that has completed, run by University of California, San Francisco. The registered enrollment target is 76 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00698035, a Phase 2 study of Sexual Dysfunction, Physiological, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical research study is to determine whether the ESTRING or a special preparation of a testosterone cream inserted vaginally are safe for use in breast cancer patients. This study will also evaluate if either of these treatments can improve symptoms of vaginal dryness or decreased sexual interest that are related to your treatment for breast cancer.
Conditions Studied
Interventions
- DRUG Testosterone Cream
- DRUG Estring
Study Locations (1)
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698035
The ClinicalTrials.gov registry entry for NCT00698035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sexual Dysfunction, Physiological appearing as the primary indexed condition, and to 2 interventions - of which Testosterone Cream is the first listed.
NCT00698035 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00698035 about?
NCT00698035 is a clinical study titled "Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients". The purpose of this clinical research study is to determine whether the ESTRING or a special preparation of a testosterone cream inserted vaginally are safe for use in breast cancer patients. This study will also evaluate if either of these treatments can improve symptoms of vaginal dryness or decre...
What is the current status of trial NCT00698035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2007-03. Estimated completion is 2012-12.
What conditions does trial NCT00698035 study?
This clinical trial studies the following conditions: Sexual Dysfunction, Physiological.
What interventions are being tested in trial NCT00698035?
The interventions under investigation include: Testosterone Cream (DRUG), Estring (DRUG).
Who is sponsoring clinical trial NCT00698035?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00698035 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sexual Dysfunction, Physiological
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.